JP7470041B2 - アルツハイマー病の判定薬および判定方法 - Google Patents

アルツハイマー病の判定薬および判定方法 Download PDF

Info

Publication number
JP7470041B2
JP7470041B2 JP2020535789A JP2020535789A JP7470041B2 JP 7470041 B2 JP7470041 B2 JP 7470041B2 JP 2020535789 A JP2020535789 A JP 2020535789A JP 2020535789 A JP2020535789 A JP 2020535789A JP 7470041 B2 JP7470041 B2 JP 7470041B2
Authority
JP
Japan
Prior art keywords
disease
alzheimer
s38aa
antibody
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020535789A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020032027A5 (https=
JPWO2020032027A1 (ja
Inventor
篤志 大野
康博 寺西
雅典 楠本
雅一 橋本
昌次 柏原
まき 橋本
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sumitomo Pharma Co Ltd
Original Assignee
Sumitomo Dainippon Pharma Co Ltd
Sumitomo Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Dainippon Pharma Co Ltd, Sumitomo Pharma Co Ltd filed Critical Sumitomo Dainippon Pharma Co Ltd
Publication of JPWO2020032027A1 publication Critical patent/JPWO2020032027A1/ja
Publication of JPWO2020032027A5 publication Critical patent/JPWO2020032027A5/ja
Priority to JP2024014251A priority Critical patent/JP7654126B2/ja
Application granted granted Critical
Publication of JP7470041B2 publication Critical patent/JP7470041B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
JP2020535789A 2018-08-07 2019-08-06 アルツハイマー病の判定薬および判定方法 Active JP7470041B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024014251A JP7654126B2 (ja) 2018-08-07 2024-02-01 アルツハイマー病の判定薬および判定方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2018148924 2018-08-07
JP2018148924 2018-08-07
PCT/JP2019/030904 WO2020032027A1 (ja) 2018-08-07 2019-08-06 アルツハイマー病の判定薬および判定方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024014251A Division JP7654126B2 (ja) 2018-08-07 2024-02-01 アルツハイマー病の判定薬および判定方法

Publications (3)

Publication Number Publication Date
JPWO2020032027A1 JPWO2020032027A1 (ja) 2021-09-09
JPWO2020032027A5 JPWO2020032027A5 (https=) 2022-08-01
JP7470041B2 true JP7470041B2 (ja) 2024-04-17

Family

ID=69413505

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020535789A Active JP7470041B2 (ja) 2018-08-07 2019-08-06 アルツハイマー病の判定薬および判定方法
JP2024014251A Active JP7654126B2 (ja) 2018-08-07 2024-02-01 アルツハイマー病の判定薬および判定方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024014251A Active JP7654126B2 (ja) 2018-08-07 2024-02-01 アルツハイマー病の判定薬および判定方法

Country Status (10)

Country Link
US (1) US12000844B2 (https=)
EP (1) EP3835424A4 (https=)
JP (2) JP7470041B2 (https=)
KR (1) KR20210041035A (https=)
CN (1) CN112567039B (https=)
AU (1) AU2019318888A1 (https=)
CA (1) CA3108440A1 (https=)
MX (1) MX2021001507A (https=)
TW (1) TW202035438A (https=)
WO (1) WO2020032027A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115066610A (zh) * 2020-02-05 2022-09-16 住友制药株式会社 用于tau病变和痴呆相关疾病的确定试剂和确定方法
AU2021218735A1 (en) * 2020-02-13 2022-09-01 Cognition Therapeutics, Inc. Method of decreasing amyloid beta monomer levels in patients with cognitive decline
WO2023036105A1 (zh) * 2021-09-09 2023-03-16 上海日馨医药科技股份有限公司 治疗神经退行性疾病的方法
CN117447590B (zh) * 2023-11-23 2024-04-26 中国检验检疫科学研究院 一种抗赤羽病病毒单克隆抗体、分泌抗赤羽病病毒单克隆抗体的杂交瘤细胞及其应用
CN121272033A (zh) * 2025-08-21 2026-01-06 广东益尔生物技术有限公司 一种Circ-sAPPα及sAPPα-199aa作为阿尔茨海默症的检测标志物的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010004849A1 (ja) 2008-07-08 2010-01-14 住友ベークライト株式会社 ポジ型感光性樹脂組成物、硬化膜、保護膜、絶縁膜およびそれらを用いた半導体装置、表示体装置
WO2012091138A1 (ja) 2010-12-28 2012-07-05 大日本住友製薬株式会社 アルツハイマー病の診断薬及び診断方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005214382B2 (en) 2004-02-19 2011-08-04 Genentech, Inc. CDR-repaired antibodies
WO2010048497A1 (en) * 2008-10-24 2010-04-29 Genizon Biosciences Inc. Genetic profile of the markers associated with alzheimer's disease
CN109924024B (zh) 2013-03-05 2021-11-23 现特技术有限公司 光子调制管理系统
CN115066610A (zh) * 2020-02-05 2022-09-16 住友制药株式会社 用于tau病变和痴呆相关疾病的确定试剂和确定方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010004849A1 (ja) 2008-07-08 2010-01-14 住友ベークライト株式会社 ポジ型感光性樹脂組成物、硬化膜、保護膜、絶縁膜およびそれらを用いた半導体装置、表示体装置
WO2012091138A1 (ja) 2010-12-28 2012-07-05 大日本住友製薬株式会社 アルツハイマー病の診断薬及び診断方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
J Alzheimers Dis，2019年10月15日，Vol.71, No.4，pp.1163-1174

Also Published As

Publication number Publication date
JP7654126B2 (ja) 2025-03-31
EP3835424A1 (en) 2021-06-16
EP3835424A4 (en) 2022-05-04
US20210165002A1 (en) 2021-06-03
CN112567039A (zh) 2021-03-26
CN112567039B (zh) 2024-11-26
CA3108440A1 (en) 2020-02-13
MX2021001507A (es) 2021-04-28
JP2024054181A (ja) 2024-04-16
KR20210041035A (ko) 2021-04-14
AU2019318888A1 (en) 2021-03-18
WO2020032027A1 (ja) 2020-02-13
US12000844B2 (en) 2024-06-04
JPWO2020032027A1 (ja) 2021-09-09
TW202035438A (zh) 2020-10-01

Similar Documents

Publication Publication Date Title
JP7654126B2 (ja) アルツハイマー病の判定薬および判定方法
JP7752533B2 (ja) タウオパチーおよび認知症関連疾患の判定薬および判定方法
JP2013092538A (ja) 脳損傷関連障害の診断法
KR101883515B1 (ko) 알츠하이머 병의 진단약 및 진단 방법
EP2817632B1 (en) New dual biomarker of neurodegeneration and of neuroregeneration
HK40048565A (en) Diagnostic drug and diagnostic method for alzheimer's disease
HK40077327A (en) Determination agent and determination method for tauopathy and dementia-related diseases
JP7343862B2 (ja) 血管障害の判定方法
Mukherjee et al. BRAIN COMMUNICATIONS AIN COMMUNICATIONS
HK1187404B (en) Diagnostic drug and diagnostic method for alzheimer's disease

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220722

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220722

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230627

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230825

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20231114

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240201

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240206

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240402

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240405

R150 Certificate of patent or registration of utility model

Ref document number: 7470041

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150